论文部分内容阅读
目的:分析孟鲁司特不同疗程对儿童毛细支气管炎临床症状的影响。方法:选取2013年1月~2014年1月在该院诊治的180例毛细支气管炎患儿为研究对象,随机平均分为3组。在控制患儿急性期症状后,A组口服孟鲁司特6个月,B组口服孟鲁司特3个月,C组不采取任何治疗措施。观察3组患儿哮喘发生情况。结果:与C组比较,A组和B组患儿发生哮喘概率较小(P<0.05);与B组比较,A组患儿发生哮喘概率较小(P<0.05)。结论:在控制毛细支气管炎患儿急性期症状后给予孟鲁司特药物治疗临床疗效较好,且持续治疗时间越长临床哮喘发生率越低,有积极的临床治疗作用,值得临床推广。
Objective: To analyze the influence of different courses of montelukast on clinical symptoms of children bronchiolitis. Methods: A total of 180 children with bronchiolitis diagnosed and treated in our hospital from January 2013 to January 2014 were selected and randomly divided into three groups. In the control of children with acute symptoms, group A montelukast oral 6 months, group B montelukast oral 3 months, C group did not take any treatment. The incidence of asthma in 3 groups was observed. Results: Compared with group C, the incidence of asthma in group A and group B was smaller (P <0.05). Compared with group B, the incidence of asthma in group A was smaller (P <0.05). Conclusion: The clinical efficacy of montelukast in the treatment of patients with bronchiolitis after acute symptoms is better, and the longer the continuous treatment time is, the lower the incidence of clinical asthma is. It has a positive clinical therapeutic effect and is worthy of clinical promotion.